Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexapro

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

Boehringer Ingelheim headquarters

Boehringer to cut another 178 jobs in France

Salesforce expected to bear brunt of the move

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Lundbeck losses deepen on EU fine

Pay-for-delay penalty contributes to operating loss of 506m Danish krone

- PMLiVE

Valeant to slash workforce after Bausch + Lomb takeover

Expects job cuts of 10 to 15 per cent

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

J&J gets pharma Q2 results off to a flying start

OTC recovery and Synthes acquisition help boost sales performance

Evotec shutters chemistry operations to exit India

Thane facility to close with loss of 120 jobs

- PMLiVE

A tailored approach to the BRIC markets

Patience, long-term thinking and strategies that are tailored to each market are key to pharma success in the BRIC countries and other emerging markets

- PMLiVE

Lundbeck to cut 50 jobs in Europe

Part of restructuring operations to cope with patent loss for Cipralex/ Lexapro

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links